Highview Merger Corp.

# Signal Note: Driehaus Capital Initiates Highview Merger Corp Position Driehaus's $5.1M entry into HVMCW (750k shares) signals conviction in the SPAC's undisclosed biotech target, likely a clinical-stage asset given Driehaus's growth focus and typical SPAC valuations. Without announced merger details, the position timing suggests either pre-announcement accumulation or conviction in a sponsor's pipeline—key catalysts to monitor include merger announcement, target identity disclosure, and near-term clinical data readouts. This warrants tracking the SPAC's SEC filings and sponsor track record to assess whether the target aligns with Driehaus's biotech thesis.